ABSTRACT The impact of prior treatment on results of clinical trials in chronic obstructive pulmonary disease (COPD) has been debated. We used data from the Study to Understand Mortality and Morbidity in COPD Trial to examine the impact of prior treatment on the effects of randomised study drugs on mortality and exacerbations.
Introduction
Clinical trials in chronic obstructive pulmonary disease (COPD) often require recruited patients to discontinue their usual inhaled respiratory medications before they are randomised to study interventions [1] [2] [3] [4] . As these trials also require patients to be clinically stable at the time of their enrolment, this approach leads to the withdrawal of what is effective treatment for many patients. This can potentially lead to a withdrawal effect, where events are seen soon after stopping a treatment and entering a trial. However, there can be later and more subtle effects of changing treatment as part of entering a trial. Subsequent randomisation to a new regimen may be superior to the previous treatment, similarly effective or less effective. The latter may occur when patients are randomised from active treatment to a placebo or an inferior treatment regime. This may impact events in the longer term; for example, affecting exacerbation rates subsequent to study entry. Although the methodology of discontinuation of existing medication is common, it is not the same as recruiting a treatment-naïve population in which all randomised patients are started on new therapy where there is no potential for a withdrawal effect. Thus, recruitment of patients on maintenance therapies can impact individual patient safety and outcomes as well as the interpretation of trials as a whole [5] .
The potential for this approach to bias the results of large clinical trials has been discussed most frequently for studies of inhaled corticosteroids (ICS) with exacerbations as the outcome [5] [6] [7] . In these trials, patients already taking ICS were randomised either to continue to take them or to have them withdrawn while those who were ICS naïve were randomised to start them de novo or to start a placebo. When the effect of ICS on exacerbation risk was examined separately in the ICS pre-treated and ICS naïve groups in the OPTIMAL trial, the benefit of randomisation to ICS was only apparent in the pre-treated group [5] . In contrast, an analysis of the TORCH study showed that ICS and ICS/long-acting β 2 -agonists (LABA) (as well as LABA alone) reduced the risk of exacerbations compared with placebo regardless of whether patients were taking ICS prior to randomisation [7] . This TORCH analysis also showed a reduction in exacerbations with active treatments regardless of prior LABA use, but there are no other published data about the impact of prior long-acting muscarinic antagonist or LABA use on outcomes.
The recently published Study to Understand Mortality and Morbidity in COPD Trial (SUMMIT) is one of the largest COPD studies ever conducted, randomising >16 000 patients with heightened cardiovascular risk to ICS alone (fluticasone furoate (FF)), LABA alone (vilanterol (VI)), combination ICS/LABA (FF/VI), or matched placebo to compare survival [2] . The trial provides a unique opportunity to examine the impact of prior medication use on the mortality and risk of exacerbations after randomisation, as well as study the safety issues around entering previously treated patients with moderate COPD into a placebo-controlled trial. These analyses are all post hoc subgroup analyses that should be interpreted with caution.
Methods
Study design and patients Details of the study have been published previously [2, 8] . Briefly, this was a prospective, double-blind, parallel-group, placebo-controlled, event-driven, randomised trial conducted at 1368 centres in 43 countries. Participants had moderate COPD according to the Global Initiative for Chronic Obstructive Lung Disease and heightened cardiovascular risk. Participants were allocated equally to one of four treatments ( placebo, FF (100 µg; GlaxoSmithKline, Brentford, UK), VI (25 µg; GlaxoSmithKline) or FF/VI (100/25 µg; Relvar/Breo, GlaxoSmithKline)) administered once daily as a dry powder with the use of an inhaler (Ellipta, GlaxoSmithKline). The primary outcome was mortality, and the secondary outcomes were on-treatment rates of decline in forced expiratory volume in 1 s (FEV1), and the on-treatment composite cardiovascular endpoint of cardiovascular death, myocardial infarction, stroke, unstable angina and transient ischaemic attack. All patients provided written informed consent. The study was approved by local ethics committees and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study is registered at www.clinicaltrials.gov with identifier number NCT01313676.
Outcome measurements and analyses
For these analyses, we examined mortality and exacerbations. As this was an event-driven study in which follow-up continued until ⩾1000 deaths had occurred, survival status was assessed by all study sites at the "common end date", January 25, 2015. The median study exposure was 1.8 years.
To evaluate the effect of prior medication on treatment estimates during the study, we analysed the population as they were randomised. Mortality was analysed using a Cox proportional hazards model allowing for covariates of age and sex. Exacerbations were assessed every 3 months and at the end of study treatment. Time to first exacerbation was analysed using a Cox proportional hazards model allowing for covariates of age, sex and exacerbations in the 12 months prior to study entry. Moderate exacerbations were defined as a symptomatic deterioration requiring treatment with antibiotic agents and/or systemic corticosteroids, whereas severe exacerbations of COPD were those leading to hospital admission. For these analyses, the reduction in exacerbation risk was expressed as a percentage derived from the hazards ratio of the analysis of time to first exacerbation. Additional post hoc analyses were performed to investigate the effect of withdrawal of medications prior to the study. Prior therapy was defined as taking a long-term COPD medication (⩾30 days) and stopping this medication prior to enrolment. Subjects within each treatment arm were categorised to one of four groups: not withdrawn from inhaled maintenance COPD medication (none); withdrawn from ICS alone; withdrawn from a long-acting bronchodilator (LABD) alone; or withdrawn from a combination of ICS and a LABD, most often a fixed ICS/LABA combination. As few patients were previously on ICS alone or on only LABD, we report these analyses in the supplementary material only.
To evaluate safety, we also analysed the time to death in subjects on placebo to assess the effect of baseline treatment. As covariates in the analysis, we included age, sex, baseline FEV1, cardiovascular risk, history of exacerbations, race, region, smoking status at screening, and indicators of ischaemic and vascular disease.
Results
Of the 16 485 patients included in the intention-to-treat analysis, we had information on previous use of inhaled medications in 16 417. At study entry, 9423 (57%) were treatment naïve regarding inhaled COPD maintenance treatment, 643 (4%) were on an ICS alone, 1734 (11%) were on an inhaled LABD alone, and 4617 (28%) were on a combination of ICS and one or more LABD. Apart from those on ICS before entering the study having a higher proportion of former smokers and exacerbators, there were no differences between the groups (table 1). As expected, these four subgroups of previous treatment were distributed similarly between the four study treatment groups ( placebo, FF, VI and FF/VI) as a result of the large study population.
Outcomes according to prior treatment
As previously reported, FF/VI did not reduce overall mortality compared with placebo: relative reduction 12% (95% CI −4-26%) [2] . However, variations existed when data were split into subgroups. When analysing the effect of randomised treatment on mortality for each of the pre-treatment groups, the treatment effect varied widely (figure 1 and figure S1). Patients previously on both ICS and one or more LABD seemed to have a better effect from using any study treatment (FF, VI or FF/VI) compared with placebo, with the difference being greatest in those randomised to FF/VI where there was a 35% (95% CI 11-52%) lower risk of mortality than those randomised to placebo (figure 1b). The corresponding reductions were 24% (95% CI −3-44%) in patients randomised to FF and 19% (95% CI −9-40%) in those randomised to VI. For those previously on either ICS alone or a LABD alone, there was no clear pattern ( figure S1 ). We performed a global test of interaction for the medications on mortality: p=0.440.
We subsequently analysed time to first moderate or severe COPD exacerbation. In the overall study, all three treatments reduced risk of exacerbations, by 10% (95% CI 2-18%), 12% (95% CI 4-19%) and 29% (95% CI 22-35%) for the VI, FF and FF/VI groups, respectively. As shown in table 2, figure 2 and figure S2, the reductions in risk of exacerbations varied considerably, as illustrated by the wide 95% confidence intervals, but there were no consistent differences from the overall study findings. The global test of interaction for the medications on exacerbations resulted in a p-value of 0.450.
Safety of being allocated to placebo
Although patients in SUMMIT were randomly allocated to placebo, FF, VI or FF/VI, and therefore have similar study exposure, this is not the case when we look at groups defined according to prior treatment. Study exposure for treatment-naïve patients was 1.77 years, for those having had ICS alone 2.15 years, LABD alone 2.08 years and prior combination treatment 2.06 years, highlighting the need for a survival analysis rather than simply comparing the percentage of deaths in each group. In the analysis within the group randomised to placebo, we found no effect of prior treatment on mortality. The hazard ratio for prior ICS alone versus no prior treatment was 0.97 (95% CI 0.53-1.78), for prior LABD alone versus no prior treatment 0.79 (95% CI 0.52-1.21) and for combination treatment versus no prior treatment 1.08 (95% CI 0.82-1.42).
Discussion
This is the largest study examining impact of prior use of inhaled COPD maintenance treatment on important outcomes in a randomised placebo-controlled trial. Whereas most previous analyses have focused on exacerbations only, we have, in addition, included overall mortality. Our study showed that having received ICS and/or LABD prior to study entry appeared to affect treatment effects on mortality whereas it did not seem to have a systematic bias on treatment effects regarding risk of exacerbations. It should be noted that these analyses are all post hoc subgroup analyses that should be interpreted with caution.
Patients on treatment before entering a trial will be different from those not receiving any prior treatment; i.e. there is a reason for them being on medication. In SUMMIT, this was apparent in the group with ICS as previous treatment use: they had a history of more frequent exacerbations, which is consistent with ICS being recommended for reducing the risk of exacerbations and in keeping with reports from other large studies [9] . It is unclear if these features in themselves could affect the results of a trial. Rates of exacerbations will almost invariably be higher in all groups with prior use than in treatment-naïve patients. However, although prior exacerbation history will affect risk of future exacerbations, there is little to indicate that the relative reduction of exacerbations by medical treatment varies according to exacerbation frequency. Treatment prior to study entry will also depend on where the study is carried out as treatments vary significantly across the globe, as this study has also found. This could be one of the [10] , and most recently for tiotropium on lung function decline [11, 12] .
In a placebo-controlled trial like SUMMIT, there will be patients who have their prior treatment withdrawn. Recent publications have suggested that careful withdrawal of ICS is well tolerated and not associated with exacerbation risk or any substantial loss of lung function if patients continue to take LABD [13] . However, a number of prior studies have suggested that some patients with COPD do deteriorate after stopping ICS [14, 15] , including some with mild disease [16] , and similar effects have been described for theophylline [17] . In addition, the same discussion about pre-enrolment medication has come up for a study comparing a fixed triple combination inhaler with an ICS/LABA [18, 19] . No studies have adequately examined the withdrawal of LABD or LABD/ICS on patient outcomes despite the potential implications for both clinical practice and the design of clinical trials. In SUMMIT, we chose a lower limit of FEV1 of 50% predicted in the inclusion criteria as we believed no study had shown beneficial effects of treatments that would preclude a placebo arm in this patient group. However, COPD is a heterogeneous disease with variable need for, and response to, therapy and caution should be taken when withdrawing treatments in patients in whom a physician has found more intense treatment to be indicated. Our study indicated that the effect of FF/VI on mortality is larger in those previously on an ICS/LABD than in those who were treatment naïve. However, we have made multiple comparisons in these analyses and the overall p-value of 0.440 for the mortality analysis cautions us not to overinterpret these mortality findings. In addition, the effect of those previously on LABD was also larger and no clear differential effect was seen on exacerbations. The SUMMIT trial has been criticised for withdrawing long-acting anticholinergics [20] but given that only 15% were on this drug before inclusion [2] and tiotropium could be used during the trial at the investigator's discretion, we cannot evaluate this in our analyses.
Regarding the safety aspect, our analyses showed that this type of post hoc analysis is not straightforward. We are used to analysing randomised trials on the premise that external factors are well balanced. However, in our event-driven study, there was a significant variation in study exposure when we divided the study population according to prior treatments. This is likely due to different countries being included in the study at different time points, most notably with longer study duration for patients in the USA and Western Europe. This also means that differences in prior treatment are likely to be linked to differences in healthcare, factors that are not registered and not accounted for in the analyses.
A strength of our study is its size and the presence of a placebo arm. However, it is limited to patients with moderate COPD and it is possible that this affects our findings. Yet in the TORCH study, where most patients had severe or very severe disease, previous treatment use did not affect treatment effects within the trial, indicating that COPD severity may not be a confounder. Our study also contains only patients with both COPD and cardiovascular comorbidity, but it is not immediately obvious why our findings would not be relevant for patients with either no comorbidities or additional comorbidities.
In conclusion, our findings confirm previous analyses of the TORCH trial showing no consistent effects of previous treatment use on exacerbations in a randomised controlled trial of FF, VI or FF/VI combined. However, patients withdrawn from an ICS/LABA appear to show better effects of an active treatment compared to placebo with regard to mortality. These presented analyses, however, are all post hoc subgroup analyses that should be interpreted with caution.
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